Form 8-K - Current report:
SEC Accession No. 0001104659-23-029687
Filing Date
2023-03-08
Accepted
2023-03-07 19:00:17
Documents
78
Period of Report
2023-03-07
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.01: Completion of Acquisition or Disposition of Assets
Item 3.02: Unregistered Sales of Equity Securities
Item 3.03: Material Modifications to Rights of Security Holders
Item 4.01: Changes in Registrant's Certifying Accountant
Item 5.01: Changes in Control of Registrant
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.05: Amendments to the Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm238578d1_8k.htm   iXBRL 8-K 137837
2 EXHIBIT 3.1 tm238578d1_ex3-1.htm EX-3.1 53568
3 EXHIBIT 3.2 tm238578d1_ex3-2.htm EX-3.2 137028
4 EXHIBIT 10.4 tm238578d1_ex10-4.htm EX-10.4 143042
5 EXHIBIT 10.5 tm238578d1_ex10-5.htm EX-10.5 133034
6 EXHIBIT 10.6 tm238578d1_ex10-6.htm EX-10.6 105003
7 EXHIBIT 10.7 tm238578d1_ex10-7.htm EX-10.7 125499
8 EXHIBIT 10.8 tm238578d1_ex10-8.htm EX-10.8 160939
9 EXHIBIT 10.9 tm238578d1_ex10-9.htm EX-10.9 120743
10 EXHIBIT 10.10 tm238578d1_ex10-10.htm EX-10.10 139503
11 EXHIBIT 10.11 tm238578d1_ex10-11.htm EX-10.11 56082
12 EXHIBIT 10.12 tm238578d1_ex10-12.htm EX-10.12 59845
13 EXHIBIT 10.13 tm238578d1_ex10-13.htm EX-10.13 75361
14 EXHIBIT 10.14 tm238578d1_ex10-14.htm EX-10.14 33638
15 EXHIBIT 10.15 tm238578d1_ex10-15.htm EX-10.15 37084
16 EXHIBIT 10.16 tm238578d1_ex10-16.htm EX-10.16 42015
17 EXHIBIT 14.1 tm238578d1_ex14-1.htm EX-14.1 44311
18 EXHIBIT 16.1 tm238578d1_ex16-1.htm EX-16.1 2242
19 EXHIBIT 99.1 tm238578d1_ex99-1.htm EX-99.1 14887
20 EXHIBIT 99.2 tm238578d1_ex99-2.htm EX-99.2 377541
21 EXHIBIT 99.3 tm238578d1_ex99-3.htm EX-99.3 523975
26 GRAPHIC tm238578d1_ex99-2img001.jpg GRAPHIC 44178
27 GRAPHIC tm238578d1_ex99-2img01.jpg GRAPHIC 31363
28 GRAPHIC tm238578d1_ex99-2img02.jpg GRAPHIC 40330
29 GRAPHIC tm238578d1_ex99-2img03.jpg GRAPHIC 75427
30 GRAPHIC tm238578d1_ex99-2img04.jpg GRAPHIC 26530
31 GRAPHIC tm238578d1_ex99-2img05.jpg GRAPHIC 28311
32 GRAPHIC tm238578d1_ex99-2img07.jpg GRAPHIC 69242
33 GRAPHIC tm238578d1_ex99-2img08.jpg GRAPHIC 44538
34 GRAPHIC tm238578d1_ex99-2img09.jpg GRAPHIC 36553
35 GRAPHIC tm238578d1_ex99-2img10.jpg GRAPHIC 33795
36 GRAPHIC tm238578d1_ex99-2img11.jpg GRAPHIC 10065
37 GRAPHIC tm238578d1_ex99-2img12.jpg GRAPHIC 49344
38 GRAPHIC tm238578d1_ex99-2img13.jpg GRAPHIC 36563
39 GRAPHIC tm238578d1_ex99-2img14.jpg GRAPHIC 32478
40 GRAPHIC tm238578d1_ex99-2img15.jpg GRAPHIC 22723
41 GRAPHIC tm238578d1_ex99-2img16.jpg GRAPHIC 38411
42 GRAPHIC tm238578d1_ex99-2img17.jpg GRAPHIC 14818
43 GRAPHIC tm238578d1_ex99-2img18.jpg GRAPHIC 36516
44 GRAPHIC tm238578d1_ex99-2img19.jpg GRAPHIC 29916
45 GRAPHIC tm238578d1_ex99-2img20.jpg GRAPHIC 49997
46 GRAPHIC tm238578d1_ex99-2img21.jpg GRAPHIC 17979
47 GRAPHIC tm238578d1_ex99-2img22.jpg GRAPHIC 67756
48 GRAPHIC tm238578d1_ex99-2img23.jpg GRAPHIC 33944
49 GRAPHIC tm238578d1_ex99-2img24.jpg GRAPHIC 19241
50 GRAPHIC tm238578d1_ex99-2img25.jpg GRAPHIC 46255
51 GRAPHIC tm238578d1_ex99-2img26.jpg GRAPHIC 40799
52 GRAPHIC tm238578d1_ex99-2img27.jpg GRAPHIC 28616
53 GRAPHIC tm238578d1_ex99-2img28.jpg GRAPHIC 39273
54 GRAPHIC tm238578d1_ex99-2img29.jpg GRAPHIC 32400
55 GRAPHIC tm238578d1_ex99-2img30.jpg GRAPHIC 24511
56 GRAPHIC tm238578d1_ex99-2img31.jpg GRAPHIC 33004
57 GRAPHIC tm238578d1_ex99-2img32.jpg GRAPHIC 38618
58 GRAPHIC tm238578d1_ex99-2img34.jpg GRAPHIC 19208
59 GRAPHIC tm238578d1_ex99-2img35.jpg GRAPHIC 26239
60 GRAPHIC tm238578d1_ex99-2img36.jpg GRAPHIC 41493
61 GRAPHIC tm238578d1_ex99-2img37.jpg GRAPHIC 19936
62 GRAPHIC tm238578d1_ex99-2img38.jpg GRAPHIC 17878
63 GRAPHIC tm238578d1_ex99-2img39.jpg GRAPHIC 25052
64 GRAPHIC tm238578d1_ex99-2img40.jpg GRAPHIC 23815
65 GRAPHIC tm238578d1_ex99-2img41.jpg GRAPHIC 23587
66 GRAPHIC tm238578d1_ex99-2img42.jpg GRAPHIC 25937
67 GRAPHIC tm238578d1_ex99-2img43.jpg GRAPHIC 22761
68 GRAPHIC tm238578d1_ex99-2img44.jpg GRAPHIC 40315
69 GRAPHIC tm238578d1_ex99-2img45.jpg GRAPHIC 27449
70 GRAPHIC tm238578d1_ex99-1img001.jpg GRAPHIC 3972
  Complete submission text file 0001104659-23-029687.txt   5410760

Data Files

Seq Description Document Type Size
22 XBRL TAXONOMY EXTENSION SCHEMA carm-20230307.xsd EX-101.SCH 3274
23 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE carm-20230307_def.xml EX-101.DEF 26692
24 XBRL TAXONOMY EXTENSION LABEL LINKBASE carm-20230307_lab.xml EX-101.LAB 36224
25 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE carm-20230307_pre.xml EX-101.PRE 25350
72 EXTRACTED XBRL INSTANCE DOCUMENT tm238578d1_8k_htm.xml XML 5115
Mailing Address 3675 MARKET STREET SUITE 200 PHILADELPHIA PA 19104
Business Address 3675 MARKET STREET SUITE 200 PHILADELPHIA PA 19104 2674916422
Carisma Therapeutics Inc. (Filer) CIK: 0001485003 (see all company filings)

EIN.: 262025616 | State of Incorp.: PA | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36296 | Film No.: 23714357
SIC: 2834 Pharmaceutical Preparations